Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
On Demand
Back
Favorite
Facebook
Tweet
Print
Robert H. Hyland, DPhil
Gilead Sciences, Inc.
Disclosure(s): Gilead Sciences, Inc.: Employee, Stocks/Bonds (Public Company)
Poster(s):
(P-2026) Obeldesivir for the Treatment of COVID-19 in People with Risk Factors for Progression to Severe Disease: the BIRCH Study
Saturday, October 19, 2024
12:15 PM – 1:30 PM
US PT
(P-2031)
Thorough QT/QTc Clinical Study to Evaluate the Effect of Remdesivir on Cardiac Repolarization in Healthy Participants
Saturday, October 19, 2024
12:15 PM – 1:30 PM
US PT
(P-2036) Obeldesivir for Treatment of COVID-19 in Adults and Adolescents Without Risk Factors for Progression to Severe Disease: the OAKTREE Study
Saturday, October 19, 2024
12:15 PM – 1:30 PM
US PT
